文献

J-GLOBAL ID：201602252555941111   整理番号：16A0864861

中心窩下2型脈絡膜血管新生に対する硝子体内組織プラスミノーゲン活性化因子およびラニビズマブによる併用療法

Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization

著者 (9件)： Kachi Ikuko (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Yasukawa Tsutomu (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Kato Aki (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Takase Noriaki (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Morita Hiroshi (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Kubota Ayae (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Hirano Yoshio (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Uemura Akiyoshi (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Ogura Yuichiro (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan)
資料名： Japanese Journal of Ophthalmology  (Japanese Journal of Ophthalmology)
巻： 60  号： 3  ページ： 179-186  発行年： 2016年05月 
JST資料番号： G0421C  ISSN： 0021-5155  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： ドイツ (DEU)  言語： 英語 (EN)

抄録/ポイント： 目的:中心窩下2型脈絡膜血管新生(CNV)に関連する線維性血...

シソーラス用語： ヒト ,...
準シソーラス用語： ラニビズマブ

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=16A0864861&from=J-GLOBAL&jstjournalNo=G0421C") }}

著者キーワード (4件)： Age-related macular degeneration ,  Intravitreal ranibizumab ,  Tissue plasminogen activator ,  Type 2 choroidal neovascularization

分類 (1件)： 眼の疾患の薬物療法  (GP05020E)

引用文献 (21件)：

• Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-72.
• Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y, et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology. 2009;116:2135-40.
• Kawasaki R, Wang JJ, Ji GJ, Taylor B, Oizumi T, Daimon M, et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology. 2008;115:1376-81.
• Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-31.
• Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-4.

タイトルに関連する用語 (6件)： 中心窩 ,  脈絡膜血管新生 ,  硝子体 ,  組織プラスミノーゲン活性化因子 ,  ラニビズマブ ,  併用療法